Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TriLink BioTechnologies (TriLink) has entered into an agreement with Nacalai USA (Nacalai), for the distribution of the former's modified nucleic acid products in Japan, Singapore, South Korea and Taiwan.
Subscribe to our email newsletter
The companies said that the agreement is expected to provide researchers in the Asian market access to quality modified nucleic acid products, to further advance research efforts in areas such as molecular biology and proteomics.
Richard Hogrefe, CEO of TriLink, said: “With TriLink’s unique high quality product offering and Nacalai’s key role as a bridge to bringing new technologies to the Japanese research market, we feel that we can now have yet another opportunity to advance science. We are excited to join forces with the great team at Nacalai USA.”
Toshi Ono, VP and COO of Nacalai, said: “We are excited about the opportunity to introduce TriLink’s technology to the Japanese scientific research community. We believe TriLink’s unique CleanAmp products will bring us a new business in the Japanese market.”